Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Posaconazole

FDA-approved product (suspension, oral), marketed as Noxafil, Noxafil Powdermix Kit, Posaconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Posaconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Coccidioidomycosis
  • Fungal infectious disease
  • Neutropenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC04; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA72.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Posaconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Posaconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

    NCT04825275 · start 2022-05-13

    Registered record
    Registry ID
    NCT04825275
    Conditions
    Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult
    Interventions
    Posaconazole Pill
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2022-05-13
    Completion
    2024-11-06
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult
    InterventionPosaconazole Pill
    PhaseEarly phase 1
    Registry statusTerminated

  • Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

    NCT04665037 · start 2022-02-22

    Registered record
    Registry ID
    NCT04665037
    Conditions
    Invasive Fungal Infection
    Interventions
    Posaconazole IV 6 mg/kg; Posaconazole PFS 6 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-02-22
    Completion
    2027-04-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    InterventionPosaconazole IV 6 mg/kg; Posaconazole PFS 6 mg/kg
    PhasePhase 2
    Registry statusRecruiting

  • Invasive Fungal Infections in Patients Following Stem Cell Transplant

    NCT04619147 · start 2022-01-15

    Registered record
    Registry ID
    NCT04619147
    Conditions
    Invasive Fungal Infections; Stem Cell Transplant Complications
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-15
    Completion
    2024-04-20
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections; Stem Cell Transplant Complications
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted

  • Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients

    NCT04725942 · start 2021-02-08

    Registered record
    Registry ID
    NCT04725942
    Conditions
    Pulmonary Fungal Infection
    Interventions
    Oral Posaconazole tablets
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-02-08
    Completion
    2023-06-01
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Fungal Infection
    InterventionOral Posaconazole tablets
    PhaseNot recorded
    Registry statusCompleted

  • Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

    NCT04218851 · start 2020-07-02

    Registered record
    Registry ID
    NCT04218851
    Conditions
    Invasive Aspergillosis
    Interventions
    Posaconazole IV; Posaconazole PFS; Posaconazole tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-02
    Completion
    2023-12-18
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis
    InterventionPosaconazole IV; Posaconazole PFS; Posaconazole tablet
    PhasePhase 2
    Registry statusCompleted

  • HDM201 Added to CT in R/R or Newly Diagnosed AML

    NCT03760445 · start 2019-11-15

    Registered record
    Registry ID
    NCT03760445
    Conditions
    Leukemia, Myeloid, Acute
    Interventions
    HDM201; cytarabine; anthracycline; midostaurin; liposomal cytarabine/daunorubicin; posaconazole; midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2019-11-15
    Completion
    2023-06-13
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Myeloid, Acute
    InterventionHDM201; cytarabine; anthracycline; midostaurin +3 more
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

    NCT03717623 · start 2019-08-01

    Registered record
    Registry ID
    NCT03717623
    Conditions
    Posaconazole; Pharmacokinetics; Invasive Candidiases; Invasive Aspergillosis; Invasive Mycosis; Fungal Infection; Prophylaxis
    Interventions
    Posaconazole pharmacokinetics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2019-08-01
    Completion
    2025-12-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosaconazole; Pharmacokinetics; Invasive Candidiases; Invasive Aspergillosis +3 more
    InterventionPosaconazole pharmacokinetics
    PhasePhase 4
    Registry statusRecruiting

  • Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia

    NCT04194086 · start 2018-11-01

    Registered record
    Registry ID
    NCT04194086
    Conditions
    Leukemia, Acute
    Interventions
    posaconazole oral suspensions
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2021-07-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Acute
    Interventionposaconazole oral suspensions
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

    NCT03434704 · start 2018-06-18

    Registered record
    Registry ID
    NCT03434704
    Conditions
    Transplant-Related Hematologic Malignancy; Leukemia, Acute; Myelodysplastic Syndromes; Graft Vs Host Disease; Fungal Infection
    Interventions
    Conditioning treatment "Thiotepa-Treosulfan-Fludarabine"; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-18
    Completion
    2019-10-13
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransplant-Related Hematologic Malignancy; Leukemia, Acute; Myelodysplastic Syndromes; Graft Vs Host Disease +1 more
    InterventionConditioning treatment "Thiotepa-Treosulfan-Fludarabine"; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis
    PhasePhase 2
    Registry statusCompleted

  • A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

    NCT03530683 · start 2018-05-14

    Registered record
    Registry ID
    NCT03530683
    Conditions
    Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma
    Interventions
    Maplirpacept (PF-07901801); Azacitidine; Venetoclax; Carfilzomib; Dexamethasone; Anti-CD20 Targeting agent; Isatuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-05-14
    Completion
    2024-07-18
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma
    InterventionMaplirpacept (PF-07901801); Azacitidine; Venetoclax; Carfilzomib +3 more
    PhasePhase 1
    Registry statusTerminated

  • Dosing Obese With Noxafil® Under a Trial (DONUT)

    NCT03246386 · start 2017-11-05

    Registered record
    Registry ID
    NCT03246386
    Conditions
    Morbid Obesity
    Interventions
    Posaconazole Injection [Noxafil] 300mg; Posaconazole Injection [Noxafil] 400mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-05
    Completion
    2018-09-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorbid Obesity
    InterventionPosaconazole Injection [Noxafil] 300mg; Posaconazole Injection [Noxafil] 400mg
    PhasePhase 4
    Registry statusCompleted

  • Drug/Drug Interactions With F901318

    NCT03095547 · start 2017-05

    Registered record
    Registry ID
    NCT03095547
    Conditions
    Invasive Aspergillosis
    Interventions
    cyclosporine A; Posaconazole; Pantoprazole; F901318; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2017-05
    Completion
    2017-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis
    Interventioncyclosporine A; Posaconazole; Pantoprazole; F901318 +1 more
    PhasePhase 1
    Registry statusWithdrawn

  • Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections

    NCT02805946 · start 2017-04-28

    Registered record
    Registry ID
    NCT02805946
    Conditions
    Allogeneic Stem Cell Transplant; Acute Graft Versus Host Disease; Acute Myeloid Leucaemia; Myelo Dysplastic Syndrome
    Interventions
    posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-28
    Completion
    2019-09-07
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Stem Cell Transplant; Acute Graft Versus Host Disease; Acute Myeloid Leucaemia; Myelo Dysplastic Syndrome
    Interventionposaconazole
    PhasePhase 4
    Registry statusCompleted

  • Registry of Patients Treated With Systemic Mold-Active Triazoles

    NCT03066011 · start 2017-03-16

    Registered record
    Registry ID
    NCT03066011
    Conditions
    Invasive Fungal Infection
    Interventions
    Isavuconazonium sulfate; Voriconazole; Posaconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-03-16
    Completion
    2020-04-24
    Enrolment
    2,015

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    InterventionIsavuconazonium sulfate; Voriconazole; Posaconazole
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia

    NCT03036046 · start 2017-03

    Registered record
    Registry ID
    NCT03036046
    Conditions
    Acute Myeloid Leukemia
    Interventions
    F901318 with fluconazole low dose; F901318 with fluconazole high dose; F901318 with posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2017-03
    Completion
    2018-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionF901318 with fluconazole low dose; F901318 with fluconazole high dose; F901318 with posaconazole
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn